Biopharma AI
By
Is Biopharma’s $8.5 Billion AI Investment in 2025 Across Discovery, R&D, and Commercialization Shaping the 2026 Innovation Landscape?
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma, Healthcare, and AI Infrastructure?
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
How Did Merck’s 2025 Deals Strengthen Its Pipeline and What Could They Mean for Future Growth?
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength Position It for Breakthrough Growth in 2026?
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
